Duvelisib

The Basics

What is Duvelisib?

used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or follicular lymphoma (FL)

Brand names for Duvelisib

Copiktra

How Duvelisib is classified

Antineoplastic Agents, Enzyme Inhibitors, Phosphatidylinositol 3-kinases

Duvelisib During Pregnancy

Duvelisib pregnancy category

Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.

What we know about taking Duvelisib while pregnant

N/A

Taking Duvelisib While Breastfeeding

What are recommendations for lactation if you're taking Duvelisib?

No information is available on the clinical use of duvelisib during breastfeeding. Because duvelisib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during duvelisib therapy and for at least 1 month after the last dose.

Maternal / infant drug levels

No information is available on the clinical use of duvelisib during breastfeeding. Because duvelisib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during duvelisib therapy and for at least 1 month after the last dose.

Possible effects of Duvelisib on milk supply

Relevant published information was not found as of the revision date.

Possible alternatives to Duvelisib

None listed